361 Capital’s Haemonetics HAE Stock Holding History

361 Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-24,393	Closed	-$2.44M	–	356
2018 Q4	$2.44M	Buy	24,393 +6,354	+35%	+$667K	0.5%	52
2018 Q3	$2.07M	Buy	18,039 +82	+0.5%	+$8.49K	0.45%	50
2018 Q2	$1.61M	Buy	+17,957	New	+$1.52M	0.37%	142

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

361 Capital's HAE Position: Q1 2019 in Review

361 Capital sold out of Haemonetics (HAE) in Q1 2019, closing a stake of 24,393 shares — an estimated $2.44M sold.

361 Capital first reported a position in HAE in Q2 2018 and held it in 3 quarters. The position peaked at $2.44M in Q4 2018. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

361 Capital reported no remaining Haemonetics position as of Q1 2019 after selling out during the quarter.
361 Capital sold 24,393 Haemonetics shares in Q1 2019, an estimated $2.44M.
361 Capital first reported a position in Haemonetics in Q2 2018 and held it in 3 quarters.
361 Capital's Haemonetics position peaked at $2.44M in Q4 2018.
260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on 361 Capital's 13F filing for Q1 2019, filed 7 May 2019.